Cargando…

Correlation of a commercial platform’s results with post-vaccination SARS-CoV-2 neutralizing antibody response and clinical host factors

INTRODUCTION: The objective of this study was to describe the correlation between the commercially available assay for anti-S1/RBD IgG and protective serum neutralizing antibodies (nAb) against SARS-CoV-2 in an adult population after SARS-CoV-2 vaccination, and determine if clinical variables impact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Slotkin, Rebecca, Kyriakides, Tassos C., Kundu, Anupam, Stack, Gary, Sutton, Richard E., Gupta, Shaili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464955/ https://www.ncbi.nlm.nih.gov/pubmed/37643190 http://dx.doi.org/10.1371/journal.pone.0289713

Ejemplares similares

Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects
por: Gupta, Shaili, et al.
Publicado: (2014)

Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test
por: Šimánek, Václav, et al.
Publicado: (2021)

Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests.
por: Montesinos, Isabel, et al.
Publicado: (2021)

Neutralizing Antibody Response in Dogs and Cats Inoculated with Commercial Inactivated Rabies Vaccines
por: SHIRAISHI, Rikiya, et al.
Publicado: (2013)

Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants
por: Morinaga, Yoshitomo, et al.
Publicado: (2021)

Post-Infection Immunodeficiency Virus Control by Neutralizing Antibodies
por: Yamamoto, Hiroyuki, et al.
Publicado: (2007)

Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms
por: Murji, Amyn A., et al.
Publicado: (2021)

2432: A close examination of anti-retroviral drug selection and management in the optima study
por: Huang, Yuan, et al.
Publicado: (2018)

47 Shrinking Coarsened Win Ratio and Testing of Composite Endpoint
por: Mou, Yunhan, et al.
Publicado: (2023)

Evaluation of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects
por: Saker, Kahina, et al.
Publicado: (2022)

The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin
por: Miller, Aaron L., et al.
Publicado: (2022)

Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2
por: Hofmann, Natalie, et al.
Publicado: (2022)

Host-Pathogen Coevolution and the Emergence of Broadly Neutralizing Antibodies in Chronic Infections
por: Nourmohammad, Armita, et al.
Publicado: (2016)

Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2
por: Ahn, Terrie S., et al.
Publicado: (2021)

High-Throughput Platform for Detection of Neutralizing Antibodies Using Flavivirus Reporter Replicon Particles
por: Lücke, Arlen-Celina, et al.
Publicado: (2022)

A cell-free antibody engineering platform rapidly generates SARS-CoV-2 neutralizing antibodies
por: Chen, Xun, et al.
Publicado: (2020)

An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity
por: Kostin, N. N., et al.
Publicado: (2022)

Performance evaluation of commercial short-oligonucleotide microarrays and the impact of noise in making cross-platform correlations
por: Shippy, Richard, et al.
Publicado: (2004)

Commercial antibodies and their validation
por: Voskuil, JLA
Publicado: (2014)

Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizers
por: Riahi, Saleh, et al.
Publicado: (2021)

DEVELOPMENT OF LABORATORY AND POINT OF CARE DETECTION PLATFORMS FOR COVID-19 NEUTRALIZING ANTIBODIES AND IMMUNE STATUS
por: Trudil, D., et al.
Publicado: (2023)

Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects
por: Gillot, Constant, et al.
Publicado: (2021)

The Prevalence of Peyronie's Disease in the United States: A Population-Based Study
por: Stuntz, Mark, et al.
Publicado: (2016)

Structural Bases of Coronavirus Attachment to Host Aminopeptidase N and Its Inhibition by Neutralizing Antibodies
por: Reguera, Juan, et al.
Publicado: (2012)

Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays
por: Bal, Antonin, et al.
Publicado: (2021)

Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
por: Upasani, Vinit, et al.
Publicado: (2023)

Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
por: Tran, Trung The, et al.
Publicado: (2022)

Urodynamics post stroke in patients with urinary incontinence: Is there correlation between bladder type and site of lesion?
por: Gupta, Anupam, et al.
Publicado: (2009)

Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies
por: Lokida, Dewi, et al.
Publicado: (2022)

Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies
por: Cook, Nathan, et al.
Publicado: (2021)

Author Correction: Delayed production of neutralizing antibodies correlates with fatal COVID-19
por: Lucas, Carolina, et al.
Publicado: (2021)

Correlation between In Vitro Neutralization Assay and Serological Tests for Protective Antibodies Detection
por: Bonifacio, Maria Addolorata, et al.
Publicado: (2022)

Correlation of SARS-CoV-2 Neutralization with Antibody Levels in Vaccinated Individuals
por: Chowdhury, Shazeda Haque, et al.
Publicado: (2023)

Neutralizing antibody: a savior in the Covid-19 disease
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies
por: Frey, Gary, et al.
Publicado: (2010)

Comparison of agglutinating and neutralizing antibodies to serovar hardjo in sows immunized with two commercial whole culture polivalent anti-leptospira bacterins
por: Soto, Francisco Rafael Martins, et al.
Publicado: (2008)

Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies
por: Zedan, Hadeel T., et al.
Publicado: (2022)

Human innate lymphoid cell activation by adenoviruses is modified by host defense proteins and neutralizing antibodies
por: Paris, Océane, et al.
Publicado: (2022)

Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection
por: Zhou, Fan, et al.
Publicado: (2021)

Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs
por: Diamant, Eran, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nvn57e548iuaa21bhncuqilrhn